Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS30079525HIVENSG00000165731.22protein_codingRETYesNo5979P07949
TVIS30027580HIVENSG00000165731.22protein_codingRETYesNo5979P07949
TVIS20046217HPVENSG00000165731.22protein_codingRETYesNo5979P07949
TVIS44026438HTLV-1ENSG00000165731.22protein_codingRETYesNo5979P07949
TCGA Plot Options
Drug Information
GeneRET
DrugBank IDDB00398
Drug NameSorafenib
Target IDBE0002411
UniProt IDP07949
Regulation Typeinhibitor
PubMed IDs15466206; 16507829; 17016424
CitationsWilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004 Oct 1;64(19):7099-109.@@Carlomagno F, Anaganti S, Guida T, Salvatore G, Troncone G, Wilhelm SM, Santoro M: BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst. 2006 Mar 1;98(5):326-34.@@Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, Schwartz B, Simantov R, Kelley S: Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov. 2006 Oct;5(10):835-44.
GroupsApproved; Investigational
Direct ClassificationDiarylethers
SMILESCNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1
PathwaysSorafenib Metabolism Pathway
PharmGKBPA7000
ChEMBLCHEMBL1336